BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026
BriaCell and its majority-owned subsidiary BriaPro will present four preclinical research abstracts at the SITC 41st Anniversary Annual Meeting, November 4-8, 2026, in Phoenix. Bria-OTS+ in vitro data showed immune-cell activation and tumor-cell killing across breast, prostate, and lung cancer models, including activity in PBMCs from cancer patients. BriaPro data covered BP-80 tolerability in cynomolgus monkeys (NOEL of 50 mg/kg/day, half-life 8.08-8.92 hours), the tumor-targeted checkpoint inhibitor TILsRx-001, and engineered CD80 variants with more than 130-fold stronger PD-L1 binding than wild-type.
Key figures
- Presentation count
- 4
- Bp80 noel mg kg day
- 50
- Bp80 half life hours low
- 8.08
- Bp80 half life hours high
- 8.92
- Cd80 variant pdl1 binding fold improvement
- more than 130-fold (0.23 µM vs >30 µM)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.